AI 检索
AI 阅读
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials.

Xiao-Li Wei,Yang Zhang,Hong-Yun Zhao,Wen-Feng Fang,Hui-Yan Luo,Miao-Zhen Qiu,Ming-Ming He,Ben-Yan Zou,Jie Xie,Chun-Lei Jin,Xian-Feng Zhou,Feng Wang,Feng-Hua Wang,Yu-Hong Li,Zhi-Qiang Wang,Rui-Hua Xu

The oncologist（2023）

引用 0|浏览33
暂无评分
摘要
SHR7390 0.5 mg plus camrelizumab showed a manageable safety profile. Preliminary clinical activity was reported regardless of MSI and BRAF status.
更多
查看译文
关键词
MEK inhibitor,SHR7390,anti-PD-1,camrelizumab,colorectal cancer
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要